BIOPORTO A/S revenue for the last year amounted to 31.10 M DKK, the most of which — 18.56 M DKK — came from its highest performing source at the moment, Neutrophil Gelatinase-associated Lipocalin Tests, the year earlier bringing 14.86 M DKK. The greatest contribution to the revenue figure was made by United States — last year it brought BIOPORTO A/S 17.30 M DKK.